Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Skin cancer, neuroendocrine carcinoma (Merkel cell)
Stage/Subtype:  stage III neuroendocrine carcinoma of the skin
Trial Type:  Treatment
Results 1-8 of 8 for your search:
Start Over
A Study to Investigate the Safety and Efficacy of Nivolumab and Nivolumab Plus Ipilimumab in Virus-associated Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: SCRX001-006, NCI-2016-01071, NCT02709889
Pazopanib Hydrochloride in Treating Patients with Progressive Carcinoid Tumors
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A021202, NCI-2013-00831, ALLIANCE A021202, CALGB-A021202, NCT01841736
Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 100070-003, NCI-2014-01995, 2014-000445-79, NCT02155647
Pembrolizumab in Treating Patients with Advanced Merkel Cell Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-09, NCI-2014-00848, MK-3475, NCT02267603
Study of aNK (Activated NK-92, Formerly Neukoplast) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-001, NCI-2015-01343, NCT02465957
Ramucirumab and Somatostatin Analog Therapy in Treating Patients with Locally Advanced or Metastatic Carcinoid Tumor That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-072, NCI-2016-00941, NCT02795858
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Start Over